Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) shares are set to reverse split before the market opens on Friday, August 21st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 20th.
Scinai Immunotherapeutics Stock Performance
Shares of SCNI opened at $0.25 on Friday. The stock has a 50 day moving average of $0.30 and a 200 day moving average of $0.56. The company has a market capitalization of $1.27 million, a price-to-earnings ratio of -0.23 and a beta of 2.08. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05. Scinai Immunotherapeutics has a 12 month low of $0.21 and a 12 month high of $1.97.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Hedge Funds Weigh In On Scinai Immunotherapeutics
An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its position in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. 58.41% of the stock is owned by institutional investors and hedge funds.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.
Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.
Read More
- Five stocks we like better than Scinai Immunotherapeutics
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
